What is SLNCF's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.39B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for SLNCF?

P/E (TTM) is n/a and 52-week range is $1.06 to $5.99 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s SLNCF figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for SLNCF?

The company profile lists revenue (TTM) near $267K, net income (TTM) near -$2.39B, EPS (TTM) near -$0.48 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Silence Therapeutics PLC based, and what identifiers does Chartloom list?

The company context section lists headquarters in London, GB, 62.2M shares outstanding, ISIN GB00B9GTXM62 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Silence Therapeutics PLC

$SLNCF

Health Care · Biotechnology

Run Scenarios

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Silence Therapeutics PLC is a GB-based company operating in Biotechnology industry. Silence Therapeutics plc is a global clinical-stage biotechnology company engaged in transforming people’s lives by silencing diseases through precision-engineered medicines created with proprietary siRNA (short interfering RNA) technology. The firm leverages its mRNAi GOLD platform to create siRNAs designed to precisely target and silence disease-associated genes in the liver. The firm focuses on areas of high unmet medical need with programs advancing cardiovascular disease, hematology and rare diseases. Divesiran (SLN124) is its wholly owned siRNA product candidate designed to inhibit TMPRSS6 expression in the liver. Zerlasiran is a siRNA molecule designed for the treatment of cardiovascular disease associated with elevated Lp(a), a lipoprotein in the blood. In addition to its wholly owned clinical pipeline, it has a third siRNA product candidate from its mRNAi GOLD platform in Phase I development in an undisclosed indication through its collaboration with AstraZeneca.

Employees

116

Website

www.silence-therapeutics.com/

IPO

2010-01-05

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)